Catalyst
Slingshot members are tracking this event:
Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Occurred Source:
http://ir.celgene.com/releasedetail.cfm?releaseid=981035
Related Projects
- What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma? CELG Execute By: Aug 31, 2016
Related Keywords
Lymphoma, Revlimid, Remarc Trial
